MedTrace Logo

Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01054170 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2012-08-20

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

AZD9668

2 x 30 mg oral tablets twice daily (bid) for 12 weeks

DRUG

Placebo

2 x matched placebo to oral tablet twice daily (bid) for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Professor Asger Dirksen · Gentofte Hospital, Department of Lung Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Canada
  • Denmark
  • Netherlands
  • Romania
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01054170 on ClinicalTrials.gov